The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Rodyukova I.S.
AO GK MEDSI Otradnoye;
Pirogov Russian National Research Medical University
Kryzhanovsky S.M.
Central State Medical Academy of Department of Presidential Affairs
Efficacy and safety of Aviandr in the treatment of anxiety in patients with adjustment disorders after COVID-19
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7): 131‑138
Views: 1496
Downloaded: 2
To cite this article:
Popova VB, Antonova EA, Hlyabova PM, et al. . Efficacy and safety of Aviandr in the treatment of anxiety in patients with adjustment disorders after COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry.
2024;124(7):131‑138. (In Russ.)
https://doi.org/10.17116/jnevro2024124071131
To investigate the efficacy and safety of Aviandr in the treatment of anxiety in patients with adjustment disorders after COVID-19.
A multicenter prospective open-label study included 109 patients of both sexes aged 18 to 65 years (70 women, 39 men, average age — 41.4±13.18 years) with a leading complaint of anxiety (Hamilton scale score, HAM–A ≥18 — ≤24), which arose after acute coronavirus infections. Clinical manifestations had to meet the diagnostic criteria F43.2 ICD-10. The drug Aviander was prescribed 20 mg 2 times a day for 4 weeks. At the end of taking the drug, patients were monitored for another 1 week (a delayed follow-up visit). Psychopathological, statistical and parametric research methods were used using standardized HAM-A, Montgomery—Asberg scales (MADRS), visual analog asthenia scale (VASH-A), Sheehan Disability Scale (SDS), digital character substitution test (DSST), general clinical impression scale (CGI).
Data from 109\110 patients were analyzed to evaluate efficacy\safety. Aviandr was administered 20 mg 2 times daily for 4 weeks. Patients were followed for 1 week (delayed follow-up visit) at the end of treatment. Reducing the intensity of anxiety on the HAM-A scale was — 14.2±4.92 or 69.4±22.66% by the end of treatment. The response rate to therapy (responders are patients with a decrease in the total score on the HAM-A ≥50%) was 83.49%. Remission was achieved (sum of HAM-A scores ≤7) by the end of treatment 68.81% of patients, and 79.8% of patients at the follow-up visit. Significant changes were obtained on the MADRS, VAS-A, SDS and DSST scales. According CGI 45.9% of patients had «much improved» and 43.1% of patients had «very much improved» by the end of treatment; 58.7% of patients had «much improved» and of 33.9% patients had «very much improved» at the follow-up visit. 38 adverse events were reported in 27 (24.55%) patients during the study. A definite association with study drug was reported between 5 mild adverse events in 4 (3.64%) patients. No subjects withdrew from the study due to an adverse event. Positive dynamics (reduction of anxiety symptoms, decrease in asthenia) persisted after discontinuation of the study drug. No cases of withdrawal syndrome were observed.
According to the results of the study, the anxiolytic, antidepressant, antiasthenic and pro-cognitive effects of Aviandr were observed. An increase in the social activity of patients was observed.
Authors:
Rodyukova I.S.
AO GK MEDSI Otradnoye;
Pirogov Russian National Research Medical University
Kryzhanovsky S.M.
Central State Medical Academy of Department of Presidential Affairs
Received:
15.02.2024
Accepted:
21.02.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.